PepGen Ltd (PEPG NASDAQ) stock market data APIs
$5.3918
-0.12(-2.2%)
as of December 5, 2025
Try our APIs with
free plan!
PepGen Ltd Financial Data Overview
Price chart is built with
Anychart
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Prev. Close
5.3918
Open
5.2725
High
5.5713
Low
5.1791
52 wk Range
0.88-6.72
Market Cap
374 M
Shares Outstanding
68 748 K
EPS
-0.52
Beta
1.908
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with PepGen Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PepGen Ltd data using free add-ons & libraries
Get PepGen Ltd Fundamental Data
PepGen Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -96 811 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.6283
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PepGen Ltd News
New
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
Shares of Sarepta Therapeutics SRPT rose 7% on Monday after the company announced its progress on a phase I/II study evaluating SRP-1003, an investigational small interfering RNA (siRNA) therapeutic f...
PepGen GAAP EPS of -$0.52
* PepGen press release [https://seekingalpha.com/pr/20303312-pepgen-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights] (PEPG [https://seekingalpha.com/symbol/PEPG]): Q3 GA...
BofA Lifts PepGen (PEPG) PT to $3 on Positive DM1 Data Despite Underperform Rating
PepGen Inc. (NASDAQ:PEPG) is one of the hot stocks to buy with huge upside potential. On October 9, BofA raised the firm’s price target on PepGen to $3 from $1 and maintained an Underperform rating ...
PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM Data
PepGen Inc. (NASDAQ:PEPG) is among the best fast money stocks to buy now. H.C. Wainwright has reaffirmed its ‘Buy’ rating on PepGen Inc. (NASDAQ:PEPG), while increasing the price target to $12.00 ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
